Literature DB >> 31584850

CIMT 2019: report on the 17th Annual Meeting of the Association for Cancer Immunotherapy.

Jan David Beck1, Matthias Birtel1, Erik Haefner1, Isabell Sofia Keil1, Daniel Reidenbach1, Nadja Salomon1, Ikra Gizem Yildiz1, Mustafa Diken1.   

Abstract

Entities:  

Keywords:  CIMT; cancer immunotherapy; cellular therapy; checkpoint blockade; combination therapy; personalized therapy; tumor microenvironment; tumor vaccination

Mesh：

Substances：

Year:  2019        PMID： 31584850      PMCID： PMC7227697          DOI： 10.1080/21645515.2019.1675459

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN： 2164-5515            Impact factor:   3.452


× No keyword cloud information.
  67 in total

1.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.

Authors:  K Bachmaier; C Krawczyk; I Kozieradzki; Y Y Kong; T Sasaki; A Oliveira-dos-Santos; S Mariathasan; D Bouchard; A Wakeham; A Itie; J Le; P S Ohashi; I Sarosi; H Nishina; S Lipkowitz; J M Penninger
Journal:  Nature       Date:  2000-01-13       Impact factor: 49.962

2.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer.

Authors:  Anusha-Preethi Ganesan; James Clarke; Oliver Wood; Eva M Garrido-Martin; Serena J Chee; Toby Mellows; Daniela Samaniego-Castruita; Divya Singh; Grégory Seumois; Aiman Alzetani; Edwin Woo; Peter S Friedmann; Emma V King; Gareth J Thomas; Tilman Sanchez-Elsner; Pandurangan Vijayanand; Christian H Ottensmeier
Journal:  Nat Immunol       Date:  2017-06-19       Impact factor: 25.606

3.  Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.

Authors:  Sabrina Prommersberger; Hardikkumar Jetani; Sophia Danhof; Razieh Monjezi; Thomas Nerreter; Julia Beckmann; Herrmann Einsele; Michael Hudecek
Journal:  Curr Res Transl Med       Date:  2018-04-11       Impact factor: 4.513

4.  Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist.

Authors:  Lutz Nuhn; Lien Van Hoecke; Kim Deswarte; Bert Schepens; Yupeng Li; Bart N Lambrecht; Stefaan De Koker; Sunil A David; Xavier Saelens; Bruno G De Geest
Journal:  Biomaterials       Date:  2018-03-16       Impact factor: 12.479

5.  Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs).

Authors:  Carlos Alfaro; Alvaro Teijeira; Carmen Oñate; Guiomar Pérez; Miguel F Sanmamed; Maria Pilar Andueza; Diego Alignani; Sara Labiano; Arantza Azpilikueta; Alfonso Rodriguez-Paulete; Saray Garasa; Juan P Fusco; Angela Aznar; Susana Inogés; Maria De Pizzol; Marcello Allegretti; Jose Medina-Echeverz; Pedro Berraondo; Jose L Perez-Gracia; Ignacio Melero
Journal:  Clin Cancer Res       Date:  2016-03-08       Impact factor: 12.531

6.  CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

Authors:  Hardikkumar Jetani; Irene Garcia-Cadenas; Thomas Nerreter; Simone Thomas; Julian Rydzek; Javier Briones Meijide; Halvard Bonig; Wolfgang Herr; Jordi Sierra; Hermann Einsele; Michael Hudecek
Journal:  Leukemia       Date:  2018-02-05       Impact factor: 11.528

7.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.

Authors:  Simon F Lacey; Elena J Orlando; Joseph A Fraietta; Iulian Pruteanu-Malinici; Mercy Gohil; Stefan Lundh; Alina C Boesteanu; Yan Wang; Roddy S O'Connor; Wei-Ting Hwang; Edward Pequignot; David E Ambrose; Changfeng Zhang; Nicholas Wilcox; Felipe Bedoya; Corin Dorfmeier; Fang Chen; Lifeng Tian; Harit Parakandi; Minnal Gupta; Regina M Young; F Brad Johnson; Irina Kulikovskaya; Li Liu; Jun Xu; Sadik H Kassim; Megan M Davis; Bruce L Levine; Noelle V Frey; Donald L Siegel; Alexander C Huang; E John Wherry; Hans Bitter; Jennifer L Brogdon; David L Porter; Carl H June; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

8.  Spontaneous tumor rejection by cbl-b-deficient CD8+ T cells.

Authors:  Stefanie Loeser; Karin Loser; Martijn S Bijker; Manu Rangachari; Sjoerd H van der Burg; Teiji Wada; Stefan Beissert; Cornelis J M Melief; Josef M Penninger
Journal:  J Exp Med       Date:  2007-04-02       Impact factor: 14.307

9.  Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes.

Authors:  Marvin H Gee; Arnold Han; Shane M Lofgren; John F Beausang; Juan L Mendoza; Michael E Birnbaum; Michael T Bethune; Suzanne Fischer; Xinbo Yang; Raquel Gomez-Eerland; David B Bingham; Leah V Sibener; Ricardo A Fernandes; Andrew Velasco; David Baltimore; Ton N Schumacher; Purvesh Khatri; Stephen R Quake; Mark M Davis; K Christopher Garcia
Journal:  Cell       Date:  2017-12-21       Impact factor: 41.582

10.  Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Authors:  Sara Bobisse; Raphael Genolet; Annalisa Roberti; Janos L Tanyi; Julien Racle; Brian J Stevenson; Christian Iseli; Alexandra Michel; Marie-Aude Le Bitoux; Philippe Guillaume; Julien Schmidt; Valentina Bianchi; Denarda Dangaj; Craig Fenwick; Laurent Derré; Ioannis Xenarios; Olivier Michielin; Pedro Romero; Dimitri S Monos; Vincent Zoete; David Gfeller; Lana E Kandalaft; George Coukos; Alexandre Harari
Journal:  Nat Commun       Date:  2018-03-15       Impact factor: 14.919
View more
  1 in total

1.  Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.

Authors:  Sayed Shahabuddin Hoseini; Madelyn Espinosa-Cotton; Hong-Fen Guo; Nai-Kong V Cheung
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.